Y-mAbs pushes back re-submission of its neuroblastoma BLA to end of 2021

Y-mAbs pushes back re-submission of its neuroblastoma BLA to end of 2021

Submitted by admin on June 23, 2021 - 10:41am
Source: 
Endpoints
News Tags: 
Y-mAbs Therapeutics
neuroblastoma
FDA
omburtamab
Headline: 
Y-mAbs pushes back re-submission of its neuroblastoma BLA to end of 2021
snippet: 

Y-mAbs Therapeutics on Wednesday again adjusted its timeline for re-submitting its neuroblastoma drug omburtamab to the FDA, saying the submission won’t likely happen until the end of 2021.

Do Not Allow Advertisers to Use My Personal information